Frisone Daniele, Chappuis Pierre O
Service d'oncologie, Hôpitaux Universitaires de Genève, Geneva, Switzerland.
Service d'oncologie de précision, Hôpitaux Universitaires de Genève, Geneva, Switzerland.
Praxis (Bern 1994). 2023;112(3):184-188. doi: 10.1024/1661-8157/a003979.
Dermatologic and rheumatologic toxicities are frequent adverse events during treatment with immune checkpoint inhibitors in oncology. Timely identification of these events and the referral to the oncologist or dermatologist are important in daily practice, such an organ damage involvements can be severe and sometimes life-threatening. The diagnosis and management of cutaneous toxicities, such as maculopapular rash and bullous dermatitis in particular, must be based on the body surface affected by skin lesions. Corticosteroids are basic treatment in moderate to severe cases. Rheumatologic toxicities are rarer and more heterogeneous, and they are often underestimated. They can occur in the absence of autoantibodies, and myositis can be life-threatening.
在肿瘤学中，皮肤和风湿毒性是免疫检查点抑制剂治疗期间常见的不良事件。在日常实践中，及时识别这些事件并转诊给肿瘤学家或皮肤科医生很重要，因为此类器官损伤可能很严重，有时甚至危及生命。皮肤毒性的诊断和管理，尤其是斑丘疹和大疱性皮炎等，必须基于受皮肤病变影响的体表部位。皮质类固醇是中重度病例的基本治疗方法。风湿毒性较为罕见且更为多样，常常被低估。它们可在无自身抗体的情况下发生，且肌炎可能危及生命。
